X

Trial Profile

The feasibility study of TAS-118 plus Oxaliplatin or TAS-118 monotherapy as perioperative chemotherapy for locally advanced gastric cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 26 Feb 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gimeracil/oteracil/tegafur/folinic acid (Primary) ; Oxaliplatin (Primary)
Indications Gastric cancer
Focus Therapeutic Use
Acronyms APOLLO-11

Most Recent Events

17 Jan 2021 Results (n=45) assessing feasibility of peri (pre and post)-operative chemotherapy with TAS-118 plus oxaliplatin or TAS-118 monotherapy in patients with locally advanced resectable gastric cancer, presented at the 2021 Gastrointestinal Cancers Symposium.
06 Nov 2020 Status changed from active, no longer recruiting to completed.
25 Jan 2020 Results presented at the 2020 Gastrointestinal Cancers Symposium

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com